2 results
Approved WMOCompleted
Part I (single ascending dose):To evaluate the safety and tolerability of ascending single doses of DRL-17822 in healthy male subjects;To evaluate the pharmacokinetics of ascending single doses of DRL-17822 in healthy male subjects;To determine CETP…
Approved WMOWill not start
Primary objective:* To demonstrate that subjects who receive an 8-day series of Otelixizumab infusions have greater improvement than subjects who receive placebo in endogenous insulin secretion at 12 months after study drug administration. Secondary…